About ADHDinfoNinja

ADHDinfoNinja is a curated ADHD information hub based in New Zealand. We provide comprehensive resources about ADHD medications available in New Zealand including methylphenidate (Ritalin, Rubifen, Concerta), lisdexamfetamine (Vyvanse), dexamfetamine, and atomoxetine.

Our medication resources cover Medsafe data sheets, Pharmac funding and Special Authority information, the New Zealand Formulary, bpacnz prescribing guides, and international clinical guidelines from AADPA, NICE, and CADDRA.

We also curate ADHD news from leading sources, scientific studies from journals including The Lancet Psychiatry, JAMA, Nature, and Cochrane Reviews, plus books, podcasts, blogs, videos, and support groups for the ADHD community in New Zealand and internationally.

Key Resources

• ADHD Medications in New Zealand
• ADHD NZ Resources
• ADHD Scientific Studies
• ADHD News
• ADHD Books
• ADHD Podcasts
• NZ Support Groups
• Online ADHD Communities
• Helpful ADHD Sources

2025 NZ ADHD Medication Updates

From February 2026, GPs and nurse practitioners in New Zealand can prescribe ADHD stimulant medications to adults without specialist referral. Pharmac funded Vyvanse (lisdexamfetamine) from December 2024 and removed two-yearly renewal criteria for all ADHD stimulant Special Authorities. Pharmac has also proposed funding Methylphenidate Sandoz XR to address ongoing global supply shortages.

ADHD in New Zealand

ADHD affects approximately 5-7% of children and 2-5% of adults worldwide. In New Zealand, stimulant medications including methylphenidate and lisdexamfetamine are classified as Class B controlled drugs regulated by Medsafe. Funding is managed by Pharmac through Special Authority approvals.